Clinical, Regulatory and Safety, Cerner Enviza

15/03/2022
05/02/2025
Institution
Non-Pharmaceutical company
Download as PDF
Institution identification

Institution ID

46259

Institution full name and acronym

Clinical, Regulatory and Safety, Cerner Enviza

Institution countries

Germany

Type of institution

Non-Pharmaceutical company

Institution website

ENCePP partner

Yes
Institution description
Cerner Enviza, Clinical,Regulatory and Safety (formerly Kantar Health) has over 40 years of experience in the field of Clinical Trials, Non-Interventional Studies, Post-Authorization Safety Studies (PASS),Registries and Epidemiological Research. With experienced in-house staff Cerner Enviza offers full-service clinical research, i.e. project management, data management, application development (EDC),site management and monitoring, safety processing/coding, biostatistics, medical writing, medical and biostatistical consultancy, quality control & SOP management. With joining Cerner Corporation in 2021,Cerner Enviza is able to enhance access to unique set of Real-World Evidence (EHR data) and advanced healthcare technology in real world safety and effectiveness research.
Institution details
Experience with collecting data directly from individual patients or respondents:
Yes
Interest in carrying out research that is funded by pharmaceutical companies:
Yes

Contact details

Studies conducted by the institution

A Long-Term Observational, Retrospective Cohort Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice in the United States and Europe
A Prospective non-interventional study (NIS) of trastuzumab deRuxtecan (T-DXd) for adult patients with advanced HER2-pOsitive gaStric or gastroesoPhageal junction (GEJ) adEnocarcinoma who have Received a prIor Trastuzumab-based regimen, accompanied by a disease registrY of patients treated with conventional therapies in a real-world setting in Europe (PROSPERITY).
A prospective, non-interventional study (NIS) with trastuzumab deruxtecan for patients with HER2-low expressing unresectable and/or metastatic breast cancer accompanied by a disease registry of patients treated with conventional chemotherapy (DESTINY Breast Respond HER2-low Europe)
An Observational Study of Upper Gastrointestinal Tract (UGIT) Bleeding Events in Patients Taking Duloxetine and NSAIDs (F1J-MC-B040)
US-based cross-sectional survey in patients taking lasmiditan: Functional REstoration with rEyvow (FREE)